K5t7S

169. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin
reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen
Psychiatry. 2006;63(11):1217-23.
170. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux LJ, Van Noord M, et al. Second-
Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Rockville
(MD): Agency for Healthcare Research and Quality (US); 2011. Informe N.º: 12-EHC012-EF
Contrato N.º: 2902-2007-10056-I.
171. Taylor D, Paton C, Kapur S. The South London and Maudsley NHS Foundation Trust &
Oxleas NHS Foundation Trust. Prescribing guidelines. 10th ed. London: Informa Healthcare;
2009.
172. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based
guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British
Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-96.
173. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian
Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the
management of major depressive disorder in adults III. Pharmacotherapy. J Affect Disord.
2009;117 Suppl 1:S26-43.
174. Agencia española del medicamento y productos sanitarios. Centro de Información online de
Medicamentos de la AEMPS - CIMA [citado 20 nov 2013]. Disponible en: http://www.aemps.
gob.es/cima/fichasTecnicas.do?metodo=detalleForm.
175. Angora-Cañego R, Esquinas-Requena JL, Agüera-Ortiz LF. Guía de selección de
psicofármacos en el anciano con patología médica concomitante Psicogeriatria. 2012;4(1):1-
19.
176. García-Herrera Pérez Bryan JM, Nogueras Morilla EV, Muñoz Cobos M, Morales Asencio
JM. Guía de Práctica Clínica para el tratamiento de la depresión en Atención Primaria.
Málaga: Distrito Sanitario Málaga-UGC Salud Mental Hospital Regional Universitario
“Carlos Haya”; 2011.
177. Undurraga J, Baldessarini R. Randomized, placebo-controlled trials of antidepressants
for acute major depression: Thirty-year meta-analytic review. Neuropsychopharmacology.
2012;37(4):851-64.
178. von Wolff A, Holzel LP, Westphal A, Harter M, Kriston L. Selective serotonin reuptake
inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and
dysthymia: a systematic review and meta-analysis. J Affect Disord. 2013;144(1-2):7-15.
179. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, et al. Comparative
benefits and harms of second-generation antidepressants for treating major depressive
disorder: an updated meta-analysis. Ann Intern Med. 2011;155(11):772-85.
180. Ou JJ, Xun GL, Wu RR, Li LH, Fang MS, Zhang HG, et al. Efficacy and safety of escitalopram
versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, doubleblind,
flexible-dose study. Psychopharmacology (Berl). 2011;213(2-3):639-46.
181. Thase ME, Ninan PT, Musgnung JJ, Trivedi MH. Remission with venlafaxine extended release
or selective serotonin reuptake inhibitors in depressed patients: A randomized, open-label
study. Prim Care Companion J Clin Psychiatry. 2011;13(1):e1-e9.
182. Martinez JM, Katon W, Greist JH, Kroenke K, Thase ME, Meyers AL, et al. A pragmatic 12-
week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors
in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin
Psychopharmacol. 2012;27(1):17-26.
Guía de Práctica Clínica sobre el manejo de la depresión en el adulto 247